The in vivo efficacy of EC31 to reverse P-gp-mediated drug resistance was investigated in three animal cancer models, including a human breast cancer tumor xenograft LCC6MDR, a human leukemia K562/P-gp model, and a murine leukemia P388ADR model. Here, PGP is linked to leukemia.